Moxidectin

As a new generation of derivative of avermectin antiparasitic drugs, moxidectin specifically binds to glutamate-gated chloride channels on the nerve cells and muscle cells of parasites, causing paralysis and death of the parasites. Compared with traditional anthelmintics, it has a broader anthelmintic spectrum, longer duration of action and lower host toxicity. At the clinical level, in the veterinary field, it is widely used for the prevention and treatment of internal and external parasites such as nematodes, mites and ticks in cattle, sheep, dogs and other animals. The human dosage form has been approved for the treatment of onchocerciasis, and it is one of the core drugs for the global river blindness elimination project, especially suitable for people with parasitic infections resistant to ivermectin.

The current global market size of moxidectin is approximately USD 320 million, and the compound annual growth rate from 2023 to 2028 is expected to reach 7.2%. The growth momentum mainly comes from the expanding demand for veterinary anthelmintics and the procurement of public health projects for human anti-filariasis. The competitive landscape presents a dual-track feature: the veterinary field is dominated by generic drugs, and Chinese enterprises account for more than 60% of the global API supply share by virtue of their production capacity advantages; the original research products still dominate the human field, and the market penetration rate of generic preparations is gradually increasing under the promotion of the domestic centralized procurement policy since 2021.

The original research enterprise of moxidectin is Pfizer Inc. of the United States, with the original research trade name for human use being Moxidectin and the original research trade name for veterinary use being Cydectin. Its core compound patent expired globally in 2015, and the dosage form patents in major markets such as China and the United States expired successively in 2020 and 2022 respectively. The approved dosage forms of the original research include veterinary injections, pour-on solutions, and human oral tablets (specification: 0.5mg). Among them, the human tablets have been included in the FDA Reference Listed Drug Catalog, but have not yet been included in the *Chinese Catalog of Chemical Drugs*. Up to now, 12 Chinese enterprises have obtained CDE registration numbers (Status A) for moxidectin APIs, no human preparations have been approved for marketing yet, and 27 product specifications of veterinary preparations have been approved. (Data as of October 2024, please refer to the official CDE website for the latest information)

In response to the R&D and quality control needs of moxidectin, CATO can provide a full set of impurity reference standards for this API. Most of the products are in stock, and orders for in-stock products placed before 16:00 will be shipped on the same day. All products comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and fully meet the full-process research needs of pharmaceutical enterprises such as registration and declaration, quality research, and batch release.